相关实验视频

Updated: May 28, 2025

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

在良性前列腺增生 (BPH) 患者中,COVID-19疫苗接种对下泌尿道 (LUTS) 的影响

Amirreza Shamshirgaran¹, Diana Taheri^1,2, Seyed Reza Yahyazadeh³

¹Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Clinical and experimental vaccine research

|February 10, 2025

概括

接种COVID-19疫苗可能会使男性良性前列腺增生 (BPH) 的尿路症状如急性和频率恶化. 在这项研究中,前列腺特异性抗原 (PSA) 水平和前列腺大小在接种疫苗后保持不变.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
免疫学免疫学免疫学
公共卫生公共卫生

背景情况:

良性前列腺增生 (BPH) 是一种非恶性前列腺扩大,导致下泌尿道症状 (LUTS).
雄激素失调是BPH发展的一个关键因素.
有关COVID-19疫苗对BPH患者LUTS的副作用存在担忧.

研究的目的:

研究COVID-19疫苗接种对BPH患者LUTS的影响.
在接种疫苗后评估前列腺特异性抗原 (PSA) 水平和前列腺体积的变化.

主要方法:

对接受COVID-19疫苗的106名BPH患者进行了前性纵向研究.
评估包括超声波,PSA测试,尿液分析和前列腺症状国际分数问卷在增强剂之前和3个月后.
使用的疫苗是牛津/阿斯特拉泽内卡,Sinopharm或斯普特尼克-V.

主要成果:

接种疫苗后没有观察到PSA水平或前列腺体积的显著变化.
尿急症,尿失尿症,尿频率和血尿症的发生率显著增加 (p<0.05).
其他尿路症状没有显示出统计学上显著的差异.

结论:

接种COVID-19疫苗可能会加剧BPH患者的特定尿路症状.
紧迫性,失尿症,频率和出血症是监测疫苗接种后关键症状.
需要进一步的研究来证实这些发现,并了解潜在的机制.

关键词:

这是一种BPH.在 COVID-19 疫情中,流血症流血症流血症下尿路症状 (LUTS) 是指下尿路的症状.疫苗接种疫苗接种

更多相关视频

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

相关概念视频

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...